BioMarin Pharmaceutical Inc. (LON:0HNC)
London · Delayed Price · Currency is GBP · Price in USD 52.84
+1.03 (1.99%)
At close: Oct 31, 2025
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,040 employees as of December 31, 2024. The number of employees decreased by 361 or -10.61% compared to the previous year.
Employees
3,040
Change (1Y)
-361
Growth (1Y)
-10.61%
Revenue / Employee
757.15K GBP
Profits / Employee
127.35K GBP
Market Cap
7.72B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3,040 | -361 | -10.61% |
| Dec 31, 2023 | 3,401 | 319 | 10.35% |
| Dec 31, 2022 | 3,082 | 37 | 1.22% |
| Dec 31, 2021 | 3,045 | -14 | -0.46% |
| Dec 31, 2020 | 3,059 | 58 | 1.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
BioMarin Pharmaceutical News
- 5 days ago - BioMarin (BMRN) Achieves FDA Priority Review for Expanded Use of Palynziq - GuruFocus
- 5 days ago - FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria - PRNewsWire
- 6 days ago - Beyond the Balance Sheet: What SWOT Reveals About BioMarin Pharmaceutical Inc (BMRN) - GuruFocus
- 6 days ago - Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday - The Motley Fool
- 6 days ago - BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy - Nasdaq
- 6 days ago - Wells Fargo Updates BioMarin Pharmaceutical (BMRN) Price Target | BMRN Stock News - GuruFocus
- 6 days ago - BioMarin Pharmaceutical (BMRN) Stock Rises on Revenue Forecast - GuruFocus
- 6 days ago - BioMarin Pharmaceutical (BMRN) Target Price Lowered by Stifel | BMRN Stock News - GuruFocus